Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Common Equity (2016 - 2025)

Historic Common Equity for Collegium Pharmaceutical (COLL) over the last 10 years, with Q3 2025 value amounting to $274.8 million.

  • Collegium Pharmaceutical's Common Equity rose 1729.95% to $274.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $274.8 million, marking a year-over-year increase of 1729.95%. This contributed to the annual value of $228.8 million for FY2024, which is 1709.61% up from last year.
  • Collegium Pharmaceutical's Common Equity amounted to $274.8 million in Q3 2025, which was up 1729.95% from $232.2 million recorded in Q2 2025.
  • Collegium Pharmaceutical's Common Equity's 5-year high stood at $274.8 million during Q3 2025, with a 5-year trough of $170.0 million in Q1 2021.
  • For the 5-year period, Collegium Pharmaceutical's Common Equity averaged around $213.7 million, with its median value being $202.9 million (2021).
  • Its Common Equity has fluctuated over the past 5 years, first soared by 6246.45% in 2021, then plummeted by 2191.29% in 2022.
  • Over the past 5 years, Collegium Pharmaceutical's Common Equity (Quarter) stood at $202.9 million in 2021, then fell by 3.98% to $194.8 million in 2022, then grew by 0.3% to $195.4 million in 2023, then grew by 17.1% to $228.8 million in 2024, then increased by 20.09% to $274.8 million in 2025.
  • Its Common Equity was $274.8 million in Q3 2025, compared to $232.2 million in Q2 2025 and $234.4 million in Q1 2025.